Wellington Management Group
RYTM icon

Wellington Management Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Wellington Management Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8M Buy
273,757
+23,601
+9% +$2.3M ﹤0.01% 936
2025
Q4 		$26.8M Buy
250,156
+225,679
+922% +$23.9M ﹤0.01% 939
2025
Q3 		$2.47M Buy
24,477
+2,052
+9% +$191K ﹤0.01% 1584
2025
Q2 		$1.42M Sell
22,425
-1,133
-5% -$69.4K ﹤0.01% 1657
2025
Q1 		$1.25M Sell
23,558
-1,997
-8% -$111K ﹤0.01% 1657
2024
Q4 		$1.43M Sell
25,555
-2,161
-8% -$119K ﹤0.01% 1651
2024
Q3 		$1.45M Sell
27,716
-174,610
-86% -$8.37M ﹤0.01% 1636
2024
Q2 		$8.31M Buy
202,326
+8,803
+5% +$351K ﹤0.01% 1209
2024
Q1 		$8.39M Buy
193,523
+53,721
+38% +$2.35M ﹤0.01% 1187
2023
Q4 		$6.43M Buy
139,802
+2,359
+2% +$74.4K ﹤0.01% 1235
2023
Q3 		$3.15M Sell
137,443
-2,778
-2% -$62.2K ﹤0.01% 1389
2023
Q2 		$2.31M Buy
140,221
+28,588
+26% +$516K ﹤0.01% 1461
2023
Q1 		$1.99M Buy
111,633
+4,717
+4% +$118K ﹤0.01% 1517
2022
Q4 		$3.11M Sell
106,916
-46,297
-30% -$1.19M ﹤0.01% 1390
2022
Q3 		$3.75M Buy
153,213
+67,648
+79% +$1.26M ﹤0.01% 1364
2022
Q2 		$355K Sell
85,565
-246
-0.3% -$1.35K ﹤0.01% 1914
2022
Q1 		$989K Sell
85,811
-660,072
-88% -$5.79M ﹤0.01% 1734
2021
Q4 		$7.44M Sell
745,883
-100,069
-12% -$1.12M ﹤0.01% 1351
2021
Q3 		$11M Sell
845,952
-450,129
-35% -$6.87M ﹤0.01% 1250
2021
Q2 		$25.4M Buy
1,296,081
+280,779
+28% +$5.83M ﹤0.01% 1034
2021
Q1 		$21.6M Sell
1,015,302
-1,085,925
-52% -$31.5M ﹤0.01% 1050
2020
Q4 		$62.5M Sell
2,101,227
-273,121
-12% -$6.94M 0.01% 704
2020
Q3 		$51.5M Sell
2,374,348
-222,575
-9% -$5.1M 0.01% 689
2020
Q2 		$57.9M Sell
2,596,923
-71,305
-3% -$1.39M 0.01% 660
2020
Q1 		$40.6M Sell
2,668,228
-652,523
-20% -$11.7M 0.01% 694
2019
Q4 		$76.2M Buy
3,320,751
+2,206,404
+198% +$49M 0.02% 647
2019
Q3 		$24.1M Buy
1,114,347
+571,717
+105% +$12.3M 0.01% 914
2019
Q2 		$11.9M Sell
542,630
-37,149
-6% -$938K ﹤0.01% 1155
2019
Q1 		$15.9M Sell
579,779
-22,735
-4% -$653K ﹤0.01% 1068
2018
Q4 		$16.2M Buy
602,514
+234,224
+64% +$6.47M ﹤0.01% 1049
2018
Q3 		$10.7M Buy
368,290
+8,215
+2% +$260K ﹤0.01% 1259
2018
Q2 		$11.3M Sell
360,075
-185,181
-34% -$5.06M ﹤0.01% 1245
2018
Q1 		$10.9M Hold
545,256
– – ﹤0.01% 1254
2017
Q4 		$15.8M Buy
+545,256
New +$14.4M ﹤0.01% 1132

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Wellington Management Group's RYTM Position: Q1 2026 in Review

Wellington Management Group increased its Rhythm Pharmaceuticals (RYTM) stake by 9.4% in Q1 2026, buying an estimated $2.3M and bringing the position to 273,757 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #936.

Wellington Management Group first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $76.2M in Q4 2019. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Wellington Management Group held 273,757 shares of Rhythm Pharmaceuticals worth $23.8M as of Q1 2026.
  • Wellington Management Group bought 23,601 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $2.3M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #936 holding.
  • Wellington Management Group first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Wellington Management Group's Rhythm Pharmaceuticals position peaked at $76.2M in Q4 2019.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.